Verastem (VSTM) Amortization of Deferred Charges (2017 - 2026)
Verastem (VSTM) posted quarterly Amortization of Deferred Charges of -$119000.0 for Q1 2026, down 496.67% year-over-year from $30000.0 in Q1 2025, and down 11800.0% quarter-over-quarter from -$1000.0 in Q2 2025.
Powered by 
Analysis
Verastem (VSTM) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Verastem's Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at -$119000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 496.67% year-over-year to -$119000.0; the TTM figure through Mar 2026 stood at -$120000.0 (down 127.03% YoY), while the FY2025 annual figure was $29000.0, up 680.0% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at -$119000.0, down from -$1000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $207000.0 in Q4 2024, with the low at -$837000.0 in Q4 2023.
- The 5-year median for Amortization of Deferred Charges is $6000.0 (2024), against an average of -$66600.0.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges tumbled 27800.0% in 2023, then surged 154.18% in 2024.
- Verastem's Amortization of Deferred Charges stood at -$3000.0 in 2022, then sank by 27800.0% to -$837000.0 in 2023, then surged by 124.73% to $207000.0 in 2024, then tumbled by 100.48% to -$1000.0 in 2025, then plunged by 11800.0% to -$119000.0 in 2026.
- Business Quant data shows VSTM's Amortization of Deferred Charges at -$119000.0 in Q1 2026, -$1000.0 in Q2 2025, and $30000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -116,000.00 |
| Mar 31, 2026 | -119,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 207,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | -419,000.00 |
| Dec 31, 2023 | -837,000.00 |
| Sep 30, 2023 | -371,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Mar 31, 2023 | -36,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | 120,000.00 |
| Jun 30, 2022 | 94,000.00 |
| Mar 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Sep 30, 2021 | 7.96 Mn |
| Jun 30, 2021 | 692,000.00 |
| Mar 31, 2021 | 636,000.00 |